Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
ErbB4/HER4 (His Tagged), Human recombinant protein
ErbB4/HER4 (His Tagged), Human Recombinant
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q15303 |
|---|---|
| Calculated MW | The recombinant human ErbB4/Fc is a disulfide-linked homodimeric protein after proteolytic removal of the signal peptide. The reduced monomer consists of 871 amino acids with a predicted molecular mass of 97.5 kDa. As a result of glycosylation, the rh ErbB4/Fc monomer migrates as approximately 125-135 kDa band in SDS-PAGE under reducing conditions. |
| Gene ID | 2066 |
|---|---|
| Gene Symbol | ERBB4 |
| Other Names | HER4, MGC138404, p180erbB4, ERBB4 |
| Gene Source | Human |
| Source | Human |
| Assay&Purity | SDS-PAGE; ≥95% |
| Assay2&Purity2 | HPLC; |
| Recombinant | Yes |
| Target/Specificity | ERBB4 |
| Format | Lyophilized |
| Storage | -80°C; Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
ErbB4, also known as Her4, is a member of the tyrosine kinase receptors (RTK) and the epidermal growth factor receptor (EGFR) subfamily, and appears to play important roles in differentiation, development and certain carcinomas. It is a single transmembrane-span type I glycoprotein structurally consisting of multiple cysteine rich domains, a transmembrane domain, a tyrosine kinase domain, a phosphotidylinositol-3 (PI-3) kinase binding site and a PDZ domain binding motif. However, the last two domains are absent in one of the two naturally occurring ErbB4 isoforms, ErbB4 CYT-2. ErbB4 ligands include the neuregulins, betacellulin and heparin-binding EGF-like growth factor (HB-EGF). Typically, heterodimerization of ErbB4 with ErbB2 forms the high affinity receptor complex, and subsequently transmit cellular signals by activating downstream src homology-2 (SH2) and phosphotyrosine binding (PTB) domain-containing signaling molecules. ErbB4 undergoes sequential processing by TNF-α converting enzyme (TACE) and presenilin-dependent gamma-secretase to release the ErbB4 ICD (4ICD) with the NLS sequence which is essential for nuclear accumulation of 4ICD. It has been shown that the ligand-induced proteolytic process of ErbB4 results in the accumulation of 4ICD and cytochrome c efflux, and directly couples a cell surface signal to the tumor cell mitochondrial apoptotic pathway. Accordingly, in contrast to the other three members of the EGFR family, ErbB4 expression seems to be selectively lost in tumors with aggressive phenotypes.
References
Plowman G.D.,et al.Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993).
Elenius K.,et al.J. Biol. Chem. 272:26761-26768(1997).
Totoki Y.,et al.Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
Culouscou J.-M.,et al.J. Biol. Chem. 268:18407-18410(1993).
Plowman G.D.,et al.Nature 366:473-475(1993).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
